COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00090753




Registration number
NCT00090753
Ethics application status
Date submitted
3/09/2004
Date registered
6/09/2004
Date last updated
14/02/2012

Titles & IDs
Public title
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Scientific title
An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia
Secondary ID [1] 0 0
BH18387
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Methoxy Polyethylene Glycol-Epoetin Beta
Treatment: Drugs - Epoetin alfa
Treatment: Drugs - Epoetin beta
Treatment: Drugs - Darbepoetin alfa

Experimental: Methoxy Polyethylene Glycol-Epoetin Beta - Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.

Active Comparator: Comparator ESA - Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.


Treatment: Drugs: Methoxy Polyethylene Glycol-Epoetin Beta
Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 µg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 µg/0.3 mL; and 360 and 400 µg/0.6 mL.

Treatment: Drugs: Epoetin alfa
Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).

Treatment: Drugs: Epoetin beta
Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).

Treatment: Drugs: Darbepoetin alfa
Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation - Blood samples were collected at each study visit, that is, every 4 weeks for the first 12 weeks, every 12 weeks until week 105 of the first study period, every 3 months thereafter, and at the end of study or the last visit if the patient discontinued the study prematurely.
Timepoint [1] 0 0
Baseline to the end of the study (Up to 49 Months)
Secondary outcome [1] 0 0
Percentage of Patients Who Had at Least 1 Adverse Event - See the adverse events section of the results for more information.
Timepoint [1] 0 0
From first dose of study drug to date of last contact or 30 days after last drug dose (Up to 49 months)

Eligibility
Key inclusion criteria
- Written informed consent

- Adult patients (= 18 years old) with chronic renal anemia

- Maintenance erythropoietic therapy with methoxy polyethylene glycol-epoetin beta or a
protocol-specified reference medication (epoetin alfa formulated with human albumin,
epoetin beta or darbepoetin alfa) in one of the following studies:
BA16528[NCT00048048], BA16285[NCT00048035], BA16286[NCT00364832],
BA16736[NCT00077597], BA16738[NCT00081471], BA16739[NCT00077610],
BA16740[NCT00077623], BA17283[NCT00077766] and BA17284[NCT00081484]

- Hemoglobin (Hb) concentration between 10.5 and 13.0 g/dL

- Adequate iron status defined as serum ferritin = 100 ng/mL or Transferrin Saturation
(TSAT)= 20% or percentage of hypochromic red blood cells (RBCs) < 10%
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Poorly controlled hypertension

- History of epileptic seizure

- Pure red cell aplasia

- Chronic congestive heart failure [New York Heart Association (NYHA) IV]

- High likelihood of early withdrawal or interruption of the study

- Active malignant disease (except non-melanoma skin cancer)

- Life expectancy less than 12 months

- Pregnancy or breast-feeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Clayton
Recruitment hospital [2] 0 0
- Gosford
Recruitment hospital [3] 0 0
- Liverpool
Recruitment hospital [4] 0 0
- Parkville
Recruitment hospital [5] 0 0
- Perth
Recruitment hospital [6] 0 0
- Sydney
Recruitment hospital [7] 0 0
- Woolloongabba
Recruitment postcode(s) [1] 0 0
3186 - Clayton
Recruitment postcode(s) [2] 0 0
2250 - Gosford
Recruitment postcode(s) [3] 0 0
1871 - Liverpool
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
6847 - Perth
Recruitment postcode(s) [6] 0 0
NSW 2148 - Sydney
Recruitment postcode(s) [7] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Vermont
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
West Virginia
Country [30] 0 0
Austria
State/province [30] 0 0
Graz
Country [31] 0 0
Belgium
State/province [31] 0 0
Aalst
Country [32] 0 0
Belgium
State/province [32] 0 0
Bruxelles
Country [33] 0 0
Belgium
State/province [33] 0 0
Edegem
Country [34] 0 0
Belgium
State/province [34] 0 0
Gent
Country [35] 0 0
Belgium
State/province [35] 0 0
Hasselt
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Liege
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Liberec
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Ostrava
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Plzen
Country [41] 0 0
Denmark
State/province [41] 0 0
Aalborg
Country [42] 0 0
Denmark
State/province [42] 0 0
Odense
Country [43] 0 0
Denmark
State/province [43] 0 0
Roskilde
Country [44] 0 0
Finland
State/province [44] 0 0
HUS
Country [45] 0 0
Finland
State/province [45] 0 0
Tampere
Country [46] 0 0
France
State/province [46] 0 0
Bayonne
Country [47] 0 0
France
State/province [47] 0 0
Bois Guillaume
Country [48] 0 0
France
State/province [48] 0 0
Bordeaux
Country [49] 0 0
France
State/province [49] 0 0
Boulogne
Country [50] 0 0
France
State/province [50] 0 0
Cabestany
Country [51] 0 0
France
State/province [51] 0 0
Caen
Country [52] 0 0
France
State/province [52] 0 0
Chambery
Country [53] 0 0
France
State/province [53] 0 0
Colmar
Country [54] 0 0
France
State/province [54] 0 0
Hyeres
Country [55] 0 0
France
State/province [55] 0 0
La Tronche
Country [56] 0 0
France
State/province [56] 0 0
Limoges
Country [57] 0 0
France
State/province [57] 0 0
Lyon
Country [58] 0 0
France
State/province [58] 0 0
Montpellier
Country [59] 0 0
France
State/province [59] 0 0
Nantes
Country [60] 0 0
France
State/province [60] 0 0
Nimes
Country [61] 0 0
France
State/province [61] 0 0
Paris
Country [62] 0 0
France
State/province [62] 0 0
Perpignan
Country [63] 0 0
France
State/province [63] 0 0
Poitiers
Country [64] 0 0
France
State/province [64] 0 0
Saint Ouen
Country [65] 0 0
France
State/province [65] 0 0
Saint-germain-en-laye
Country [66] 0 0
France
State/province [66] 0 0
Salouël
Country [67] 0 0
France
State/province [67] 0 0
Tarbes
Country [68] 0 0
France
State/province [68] 0 0
Thionville
Country [69] 0 0
France
State/province [69] 0 0
Toulouse
Country [70] 0 0
France
State/province [70] 0 0
Tours
Country [71] 0 0
Germany
State/province [71] 0 0
Bad Hersfeld
Country [72] 0 0
Germany
State/province [72] 0 0
Berlin
Country [73] 0 0
Germany
State/province [73] 0 0
Dortmund
Country [74] 0 0
Germany
State/province [74] 0 0
Erlangen
Country [75] 0 0
Germany
State/province [75] 0 0
München
Country [76] 0 0
Germany
State/province [76] 0 0
Nürnberg
Country [77] 0 0
Germany
State/province [77] 0 0
Stuttgart
Country [78] 0 0
Germany
State/province [78] 0 0
Villingen-schwenningen
Country [79] 0 0
Germany
State/province [79] 0 0
Wiesbaden
Country [80] 0 0
Germany
State/province [80] 0 0
Wiesloch
Country [81] 0 0
Germany
State/province [81] 0 0
Wuppertal
Country [82] 0 0
Greece
State/province [82] 0 0
Alexandroupolis
Country [83] 0 0
Greece
State/province [83] 0 0
Ioannina
Country [84] 0 0
Greece
State/province [84] 0 0
Larissa
Country [85] 0 0
Greece
State/province [85] 0 0
Piraeus
Country [86] 0 0
Greece
State/province [86] 0 0
Thessaloniki
Country [87] 0 0
Hungary
State/province [87] 0 0
Budapest
Country [88] 0 0
Hungary
State/province [88] 0 0
Debrecen
Country [89] 0 0
Hungary
State/province [89] 0 0
Miskolc
Country [90] 0 0
Hungary
State/province [90] 0 0
Pecs
Country [91] 0 0
Italy
State/province [91] 0 0
Bergamo
Country [92] 0 0
Italy
State/province [92] 0 0
Cagliari
Country [93] 0 0
Italy
State/province [93] 0 0
Cremona
Country [94] 0 0
Italy
State/province [94] 0 0
Cuneo
Country [95] 0 0
Italy
State/province [95] 0 0
Genova
Country [96] 0 0
Italy
State/province [96] 0 0
Lecco
Country [97] 0 0
Italy
State/province [97] 0 0
Livorno
Country [98] 0 0
Italy
State/province [98] 0 0
Lodi
Country [99] 0 0
Italy
State/province [99] 0 0
Messina
Country [100] 0 0
Italy
State/province [100] 0 0
Mestre
Country [101] 0 0
Italy
State/province [101] 0 0
Modena
Country [102] 0 0
Italy
State/province [102] 0 0
Pavia
Country [103] 0 0
Italy
State/province [103] 0 0
Prato
Country [104] 0 0
Italy
State/province [104] 0 0
Reggio Calabria
Country [105] 0 0
Italy
State/province [105] 0 0
S Fermo Della Battaglia
Country [106] 0 0
Italy
State/province [106] 0 0
Venezia
Country [107] 0 0
Mexico
State/province [107] 0 0
Cuernavaca
Country [108] 0 0
Mexico
State/province [108] 0 0
Mexico City
Country [109] 0 0
Netherlands
State/province [109] 0 0
Heerlen
Country [110] 0 0
Norway
State/province [110] 0 0
Trondheim
Country [111] 0 0
Panama
State/province [111] 0 0
Panama City
Country [112] 0 0
Poland
State/province [112] 0 0
Gdansk
Country [113] 0 0
Poland
State/province [113] 0 0
Gdynia
Country [114] 0 0
Poland
State/province [114] 0 0
Kielce
Country [115] 0 0
Poland
State/province [115] 0 0
Krakow
Country [116] 0 0
Poland
State/province [116] 0 0
Lodz
Country [117] 0 0
Poland
State/province [117] 0 0
Poznan
Country [118] 0 0
Poland
State/province [118] 0 0
Rzeszow
Country [119] 0 0
Poland
State/province [119] 0 0
Szczecin
Country [120] 0 0
Poland
State/province [120] 0 0
Warszawa
Country [121] 0 0
Poland
State/province [121] 0 0
Wolomin
Country [122] 0 0
Poland
State/province [122] 0 0
Wroclaw
Country [123] 0 0
Portugal
State/province [123] 0 0
Setubal
Country [124] 0 0
Puerto Rico
State/province [124] 0 0
Ponce
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Moscow
Country [126] 0 0
Russian Federation
State/province [126] 0 0
St Petersburg
Country [127] 0 0
South Africa
State/province [127] 0 0
Cape Town
Country [128] 0 0
South Africa
State/province [128] 0 0
Durban
Country [129] 0 0
South Africa
State/province [129] 0 0
Soweto
Country [130] 0 0
Spain
State/province [130] 0 0
Alcorcon
Country [131] 0 0
Spain
State/province [131] 0 0
Alicante
Country [132] 0 0
Spain
State/province [132] 0 0
Almería
Country [133] 0 0
Spain
State/province [133] 0 0
Badalona
Country [134] 0 0
Spain
State/province [134] 0 0
Barcelona
Country [135] 0 0
Spain
State/province [135] 0 0
Bilbao
Country [136] 0 0
Spain
State/province [136] 0 0
Córdoba
Country [137] 0 0
Spain
State/province [137] 0 0
Hospitalet de Llobregat
Country [138] 0 0
Spain
State/province [138] 0 0
La Coruna
Country [139] 0 0
Spain
State/province [139] 0 0
Lerida
Country [140] 0 0
Spain
State/province [140] 0 0
Madrid
Country [141] 0 0
Spain
State/province [141] 0 0
Malaga
Country [142] 0 0
Spain
State/province [142] 0 0
Oviedo
Country [143] 0 0
Spain
State/province [143] 0 0
Palma de Mallorca
Country [144] 0 0
Spain
State/province [144] 0 0
Salamanca
Country [145] 0 0
Spain
State/province [145] 0 0
Santander
Country [146] 0 0
Spain
State/province [146] 0 0
Santiago de Compostela
Country [147] 0 0
Spain
State/province [147] 0 0
Sevilla
Country [148] 0 0
Sweden
State/province [148] 0 0
Huddinge
Country [149] 0 0
Sweden
State/province [149] 0 0
Karlstad
Country [150] 0 0
Sweden
State/province [150] 0 0
Stockholm
Country [151] 0 0
Sweden
State/province [151] 0 0
Umea
Country [152] 0 0
Switzerland
State/province [152] 0 0
Aarau
Country [153] 0 0
Switzerland
State/province [153] 0 0
Lausanne
Country [154] 0 0
Taiwan
State/province [154] 0 0
Taichung
Country [155] 0 0
Taiwan
State/province [155] 0 0
Taipei
Country [156] 0 0
Thailand
State/province [156] 0 0
Bangkok
Country [157] 0 0
Thailand
State/province [157] 0 0
Chiang Mai
Country [158] 0 0
Thailand
State/province [158] 0 0
Chonburi
Country [159] 0 0
Thailand
State/province [159] 0 0
Phitsanulok
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Belfast
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Cambridge
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Carshalton
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Dundee
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Exeter
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Glasgow
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Leicester
Country [167] 0 0
United Kingdom
State/province [167] 0 0
London
Country [168] 0 0
United Kingdom
State/province [168] 0 0
Salford
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or
subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients
with renal anemia. Eligible patients were those who were receiving stable maintenance therapy
with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in
Phase II or III clinical studies. They continued to receive methoxy polyethylene
glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of
administration (sc or iv) as in the qualifying studies.
Trial website
https://clinicaltrials.gov/show/NCT00090753
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications